The overall goal of this initiative is to strengthen the research infrastructure for cancer research at Florida A&M University through research collaboration in a focused and coordinated effort. Despite significant discovery of chemotherapeutic agents and their mechanisms of action, the need for new chemical entities having new mechanisms of action for the treatment of breast and lung cancer remains high. Therefore, an aggressive exploitation of new anticancer agents/combination and their molecular mechanisms involved in tumor regression are planned through research collaboration. Breast and lung cancer are the most common cancer affecting minority populations and these two cancers hence been chosen to be pursued at FAMU. Furthermore, FAMU has researchers who are performing cutting edge research in these areas and hence can contribute in building a strong infrastructure for other researchers. Another impetus for this activity is to take a step towards remedy for the persistent disparity in the number of minority investigators involved in targeted cancer therapy research. The difficulty in implementing innovative approaches in cancer research at historically black colleges and universities is due to the lack of adequate resources, trained investigators and research infrastructure for breast and lung cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Exploratory Grants (P20)
Project #
5P20MD006738-02
Application #
8552028
Study Section
Special Emphasis Panel (ZMD1-RN)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
2
Fiscal Year
2013
Total Cost
$73,691
Indirect Cost
$19,512
Name
Florida Agricultural and Mechanical University
Department
Type
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Boakye, Cedar H A; Patel, Ketan; Doddapaneni, Ravi et al. (2016) Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces 143:156-67
Tawk, Rima; Dutton, Matthew (2016) Racial Differences in Length of Stay for Patients Who Leave Against Medical Advice from U.S. General Hospitals. Int J Environ Res Public Health 13:
Ramsubhag, Ron R; Massaro, Chelsea L; Dadich, Christina M et al. (2016) Synthesis of ""neoprofen"", a rigidified analogue of ibuprofen, exemplifying synthetic methodology for altering the 3-D topology of pharmaceutical substances. Org Biomol Chem 14:7855-8
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Hedrick, Erik; Lee, Syng-Ook; Doddapaneni, Ravi et al. (2016) NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration. Mol Cell Biol 36:1383-94
Gangapuram, Madhavi; Jean, Riccardo; Mazzio, Elizabeth et al. (2016) Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells. Anticancer Res 36:5043-5052
Zarmouh, Najla O; Messeha, Samia S; Elshami, Faisel M et al. (2016) Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors. European J Med Plants 15:
Patel, Ketan; Doddapaneni, Ravi; Chowdhury, Nusrat et al. (2016) Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond) 11:1377-92
Andey, Terrick; Patel, Apurva; Marepally, Srujan et al. (2016) Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS One 11:e0146804
Mochona, Bereket; Qi, Xin; Euynni, Suresh et al. (2016) Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett 26:2847-51

Showing the most recent 10 out of 81 publications